Terri Morton brings over 18 years of extensive experience in clinical pharmacology. Formerly, served as Associate Director at a biotech company, leading drug-drug interaction studies and Phase 2 efficacy and safety studies. Notably, spearheaded a groundbreaking Phase 1 study for a drug targeting rare autoimmune diseases. In earlier roles, excelled as a Senior Pharmacokineticist, overseeing Phase 1 bioavailability studies for long-acting injectable products and contributing to breast cancer treatment research. As Senior Principal Clinical Pharmacologist played a pivotal role in bringing drugs to market for acute pain management, including conducting first-in-human studies and contributing to regulatory submissions.

Dr. Morton holds a graduate degree in Pharmaceutical Science and Pharmacology from the University of Missouri at Kansas City, highly skilled in writing regulatory documents and scientific papers, demonstrating expertise in protocol development and study reporting